Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic ...

Hemophilia is a genetic bleeding disorder that prevents blood from properly clotting. Severe bleeding from minor injuries or surgery can occur. Low levels or the absence of some proteins ...

Due to hemophilia A patients switching to newer treatments, Takeda Pharmaceuticals is discontinuing both Hemofil M and Recombinate globally.

Children with hemophilia have problems with dynamic balance and face an increased risk of falls compared with healthy peers, ...

That drug, an IgG1 monoclonal antibody that helps promote clotting, was approved by the FDA in October for hemophilia A and B in adults and adolescents. The move comes after Pfizer terminated a ...

The FDA has approved the following gene therapies for hemophilia B: The tissue factor pathway inhibitor (TFPI) is another protein that limits the action of clotting factor Xa. Blocking TFPI allows ...

Hemophilia A is a bleeding disorder caused by a deficiency in clotting factor VIII (FVIII), leading to recurrent joint bleeds, musculoskeletal damage, and chronic pain. The World Federation of ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

People with hemophilia have a defect in a gene that regulates production of proteins called clotting factors. It primarily affects men and causes spontaneous and potentially severe bleeding after ...

The global hemophilia market is growing rapidly, supported by ongoing advancements in treatment approaches such as gene therapy, extended half-life clotting factors, and prophylaxis. Enhanced ...

Wiley was directed to Cornell University College of Veterinary Medicine, which operates a comparative coagulation laboratory. A test determined that Walter had hemophilia A, a blood clotting ...